{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:32:55Z","timestamp":1793154775584,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cytochrome P450 2D6 (CYP2D6) is a polymorphic enzyme that influences antidepressant metabolism. This retrospective cohort study investigated the association between\n                    <jats:italic>CYP2D6<\/jats:italic>\n                    genotype and treatment outcomes in 99 hospitalized patients with major depressive disorder (MDD) in Belgrade, Serbia. Patients were classified as poor (PM,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20095), intermediate (IM,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200921), or normal metabolizers (NM,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200973). Effectiveness and tolerability were assessed from admission to discharge (~4 weeks). Hamilton Depression Rating Scale (HAM-D) score reduction was the primary outcome; tolerability was measured using the Toronto Side Effects Scale (TSES). Compared with NMs, HAM-D score reductions were 4.3 and 9.0 points lower in IMs and PMs. TSES scores were 1.3 and 2.3 points higher in IMs and PMs, respectively. Central nervous system and gastrointestinal effects were more frequent in IMs and PMs; sexual dysfunction did not differ. Reduced CYP2D6 activity was associated with poorer outcomes, indicating the potential usefulness of\n                    <jats:italic>CYP2D6<\/jats:italic>\n                    genotyping in MDD.\n                  <\/jats:p>","DOI":"10.1038\/s41397-026-00428-y","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:36:37Z","timestamp":1787135797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between CYP2D6 genotype and treatment effectiveness and safety in 99 hospitalized patients with major depressive disorder a retrospective cohort study CYP2D6 genotype and antidepressant response"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8147-7155","authenticated-orcid":false,"given":"Aleksandra","family":"Petkovi\u0107 \u0106ur\u010din","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1380-0050","authenticated-orcid":false,"given":"Aleksandra","family":"Jeremi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Jokovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0350-4733","authenticated-orcid":false,"given":"Gordana","family":"\u0160upi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2042-7059","authenticated-orcid":false,"given":"Katarina","family":"Simi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Milosavljevi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0695-1563","authenticated-orcid":false,"given":"Zvezdana","family":"Stojanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5296-4245","authenticated-orcid":false,"given":"Marin M.","family":"Juki\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"428_CR1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"T Vos","year":"2020","unstructured":"Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020;396:1204\u201322.","journal-title":"The Lancet"},{"key":"428_CR2","unstructured":"Depression and Other Common Mental Disorders. https:\/\/www.who.int\/publications\/i\/item\/depression-global-health-estimates. Accessed 3 June2025."},{"key":"428_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1515\/IJAMH.2007.19.1.27","volume":"19","author":"ER Galaif","year":"2007","unstructured":"Galaif ER, Sussman S, Newcomb MD, Locke TF. Suicidality, depression, and alcohol use among adolescents: a review of empirical findings. International Journal of Adolescent Medicine and Health. 2007;19:27\u201336.","journal-title":"International Journal of Adolescent Medicine and Health"},{"key":"428_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1176\/appi.ajp.163.1.101","volume":"163","author":"M Olfson","year":"2006","unstructured":"Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. AJP. 2006;163:101\u20138.","journal-title":"AJP"},{"key":"428_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","volume":"163","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. AJP. 2006;163:28\u201340.","journal-title":"AJP"},{"key":"428_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","volume":"9","author":"D Warden","year":"2007","unstructured":"Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9:449\u201359.","journal-title":"Curr Psychiatry Rep"},{"key":"428_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jpsychires.2019.01.003","volume":"111","author":"JF Greden","year":"2019","unstructured":"Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study. Journal of Psychiatric Research. 2019;111:59\u201367.","journal-title":"Journal of Psychiatric Research"},{"key":"428_CR8","doi-asserted-by":"publisher","first-page":"104965","DOI":"10.1016\/j.neubiorev.2022.104965","volume":"144","author":"D Arnone","year":"2023","unstructured":"Arnone D, Omar O, Arora T, \u00d6stlundh L, Ramaraj R, Javaid S, et al. Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: systematic review and meta-analysis of randomised controlled trials. Neuroscience & Biobehavioral Reviews. 2023;144:104965.","journal-title":"Neuroscience & Biobehavioral Reviews"},{"key":"428_CR9","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/cpt.2748","volume":"112","author":"LC Brown","year":"2022","unstructured":"Brown LC, Stanton JD, Bharthi K, Maruf AA, M\u00fcller DJ, Bousman CA. Pharmacogenomic testing and depressive symptom remission: a systematic review and meta\u2010analysis of prospective, controlled clinical trials. Clin Pharma and Therapeutics. 2022;112:1303\u201317.","journal-title":"Clin Pharma and Therapeutics"},{"key":"428_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115102","volume":"321","author":"M Bunka","year":"2023","unstructured":"Bunka M, Wong G, Kim D, Edwards L, Austin J, Doyle-Waters MM, et al. Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: a rapid review and meta-analysis. Psychiatry Research. 2023;321:115102.","journal-title":"Psychiatry Research"},{"key":"428_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.euroneuro.2024.01.005","volume":"81","author":"F Milosavljevi\u0107","year":"2024","unstructured":"Milosavljevi\u0107 F, Molden ProfE, Ingelman-Sundberg ProfM, Juki\u0107 AssocP. rofMM. Current level of evidence for improvement of antidepressant efficacy and tolerability by pharmacogenomic-guided treatment: a Systematic review and meta-analysis of randomized controlled clinical trials. European Neuropsychopharmacology. 2024;81:43\u201352.","journal-title":"European Neuropsychopharmacology"},{"key":"428_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-04756-2","volume":"23","author":"X Wang","year":"2023","unstructured":"Wang X, Wang C, Zhang Y, An Z. Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT. BMC Psychiatry. 2023;23:334.","journal-title":"BMC Psychiatry"},{"key":"428_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3109\/09540261.2013.825579","volume":"25","author":"CA Altar","year":"2013","unstructured":"Altar CA, Hornberger J, Shewade A, Cruz V, Garrison J, Mrazek D. Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. International Review of Psychiatry. 2013;25:509\u201333.","journal-title":"International Review of Psychiatry"},{"key":"428_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement H, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9\u201362.","journal-title":"Pharmacopsychiatry"},{"key":"428_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cpt.2903","volume":"114","author":"CA Bousman","year":"2023","unstructured":"Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clin Pharma and Therapeutics. 2023;114:51\u201368.","journal-title":"Clin Pharma and Therapeutics"},{"key":"428_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/gim.2016.80","volume":"19","author":"A Gaedigk","year":"2017","unstructured":"Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 phenotype from genotype across world populations. Genetics in Medicine. 2017;19:69\u201376.","journal-title":"Genetics in Medicine"},{"key":"428_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cpt.147","volume":"98","author":"J Hicks","year":"2015","unstructured":"Hicks J, Bishop J, Sangkuhl K, M\u00fcller D, Ji Y, Leckband S, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharma and Therapeutics. 2015;98:127\u201334.","journal-title":"Clin Pharma and Therapeutics"},{"key":"428_CR18","unstructured":"PharmGKB. PharmGKB. https:\/\/www.pharmgkb.org\/gene\/PA128. Accessed 3 June2025."},{"key":"428_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2022.114535","volume":"312","author":"D Jokovi\u0107","year":"2022","unstructured":"Jokovi\u0107 D, Milosavljevi\u0107 F, Stojanovi\u0107 Z, \u0160upi\u0107 G, Vojvodi\u0107 D, Uzelac B, et al. CYP2C19 slow metabolizer phenotype is associated with lower antidepressant efficacy and tolerability. Psychiatry Research. 2022;312:114535.","journal-title":"Psychiatry Research"},{"key":"428_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-02981-1","volume":"14","author":"D Li","year":"2024","unstructured":"Li D, Pain O, Fabbri C, Wong WLE, Lo CWH, Ripke S, et al. Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis. Transl Psychiatry. 2024;14:296.","journal-title":"Transl Psychiatry"},{"key":"428_CR21","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.4088\/JCP.08m04773blu","volume":"71","author":"KW Lobello","year":"2010","unstructured":"Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI, et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry. 2010;71:1482\u20137.","journal-title":"J Clin Psychiatry"},{"key":"428_CR22","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.clpt.2003.12.015","volume":"75","author":"T Rau","year":"2004","unstructured":"Rau T. Cyp2d6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants\u2014a pilot study. Clinical Pharmacology & Therapeutics. 2004;75:386\u201393.","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"428_CR23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2217\/pgs.09.168","volume":"11","author":"M-H Tsai","year":"2010","unstructured":"Tsai M-H, Lin K-M, Hsiao M-C, Shen WW, Lu M-L, Tang H-S, et al. Genetic polymorphisms of cytochrome p450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics. 2010;11:537\u201346.","journal-title":"Pharmacogenomics"},{"key":"428_CR24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/01.pra.0000405363.95881.01","volume":"17","author":"I D\u2019empaire","year":"2011","unstructured":"D\u2019empaire I, Guico-Pabia CJ, Preskorn SH. Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant? Journal of Psychiatric Practice. 2011;17:330\u20139.","journal-title":"Journal of Psychiatric Practice"},{"key":"428_CR25","first-page":"433","volume":"37","author":"M Grzesiak","year":"2003","unstructured":"Grzesiak M, Besz\u0142ej A, Lebioda A, Jonkisz A, Dobosz T, Kiejna A. [Retrospective assessment of the antidepressants tolerance in the group of patients with diagnosis of depression and different CYP2D6 genotype]. Psychiatr Pol. 2003;37:433\u201344.","journal-title":"Psychiatr Pol"},{"key":"428_CR26","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1365-2125.2007.03052.x","volume":"65","author":"MJ Bijl","year":"2008","unstructured":"Bijl MJ, Visser LE, Hofman A, Vulto AG, Van Gelder T, Stricker BHCH, et al. Influence of the CYP2D6 * 4 polymorphism on dose, switching and discontinuation of antidepressants. Brit J Clinical Pharma. 2008;65:558\u201364.","journal-title":"Brit J Clinical Pharma"},{"key":"428_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/FPC.0000000000000406","volume":"30","author":"CD Jessel","year":"2020","unstructured":"Jessel CD, Mostafa S, Potiriadis M, Everall IP, Gunn JM, Bousman CA. Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients. Pharmacogenetics and Genomics. 2020;30:145\u201352.","journal-title":"Pharmacogenetics and Genomics"},{"key":"428_CR28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/01.jcp.0000155832.79777.b5","volume":"25","author":"H Mulder","year":"2005","unstructured":"Mulder H, Wilmink FW, Beumer TL, Tamminga WJ, Jedema JN, Egberts ACG. The association between cytochrome P450 2D6 genotype and prescription patterns of antipsychotic and antidepressant drugs in hospitalized psychiatric patients: a retrospective follow-up study. Journal of Clinical Psychopharmacology. 2005;25:188\u201391.","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"428_CR29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fphar.2017.00402","volume":"8","author":"A B\u00e9rard","year":"2017","unstructured":"B\u00e9rard A, Gaedigk A, Sheehy O, Chambers C, Roth M, Bozzo P, et al. Association between CYP2D6 genotypes and the risk of antidepressant discontinuation, dosage modification and the occurrence of maternal depression during pregnancy. Front Pharmacol. 2017;8:402.","journal-title":"Front Pharmacol"},{"key":"428_CR30","doi-asserted-by":"publisher","first-page":"870","DOI":"10.3390\/ph15070870","volume":"15","author":"LS Thiele","year":"2022","unstructured":"Thiele LS, Ishtiak-Ahmed K, Thirstrup JP, Agerbo E, Lunenburg CATC, M\u00fcller DJ, et al. Clinical impact of functional CYP2C19 and CYP2D6 gene variants on treatment with antidepressants in young people with depression: a danish cohort study. Pharmaceuticals. 2022;15:870.","journal-title":"Pharmaceuticals"},{"key":"428_CR31","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/FTD.0b013e31817d6f5d","volume":"30","author":"M Gex-Fabry","year":"2008","unstructured":"Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry J-M, Bondolfi G, et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Therapeutic Drug Monitoring. 2008;30:474\u201382.","journal-title":"Therapeutic Drug Monitoring"},{"key":"428_CR32","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1176\/appi.ajp.160.10.1830","volume":"160","author":"GM Murphy","year":"2003","unstructured":"Murphy GM, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. AJP. 2003;160:1830\u20135.","journal-title":"AJP"},{"key":"428_CR33","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2217\/pgs-2017-0003","volume":"18","author":"A Taranu","year":"2017","unstructured":"Taranu A, Colle R, Gressier F, El Asmar K, Becquemont L, Corruble E, et al. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings? Pharmacogenomics. 2017;18:639\u201350.","journal-title":"Pharmacogenomics"},{"key":"428_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/hup.539","volume":"19","author":"RL Roberts","year":"2004","unstructured":"Roberts RL, Mulder RT, Joyce PR, Luty SE, Kennedy MA. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Human Psychopharmacology. 2004;19:17\u201323.","journal-title":"Human Psychopharmacology"},{"key":"428_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2217\/pgs.12.203","volume":"14","author":"DJ Conrado","year":"2013","unstructured":"Conrado DJ, Rogers HL, Zineh I, Pacanowski MA. Consistency of drug\u2013drug and gene\u2013drug interaction information in US FDA-Approved drug labels. Pharmacogenomics. 2013;14:215\u201323.","journal-title":"Pharmacogenomics"},{"key":"428_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/cpt.597","volume":"102","author":"J Hicks","year":"2017","unstructured":"Hicks J, Sangkuhl K, Swen J, Ellingrod V, M\u00fcller D, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharma and Therapeutics. 2017;102:37\u201344.","journal-title":"Clin Pharma and Therapeutics"},{"key":"428_CR37","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/clpt.2011.34","volume":"89","author":"JJ Swen","year":"2011","unstructured":"Swen JJ, Nijenhuis M, De Boer A, Grandia L, Maitland-van Der Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte\u2014 an update of guidelines. Clin Pharmacol Ther. 2011;89:662\u201373.","journal-title":"Clin Pharmacol Ther"},{"key":"428_CR38","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22\u201333.","journal-title":"J Clin Psychiatry"},{"key":"428_CR39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jad.2015.03.021","volume":"180","author":"Y Hayasaka","year":"2015","unstructured":"Hayasaka Y, Purgato M, Magni LR, Ogawa Y, Takeshima N, Cipriani A, et al. Dose equivalents of antidepressants: evidence-based recommendations from randomized controlled trials. Journal of Affective Disorders. 2015;180:179\u201384.","journal-title":"Journal of Affective Disorders"},{"key":"428_CR40","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cts.12692","volume":"13","author":"KE Caudle","year":"2020","unstructured":"Caudle KE, Sangkuhl K, Whirl\u2010Carrillo M, Swen JJ, Haidar CE, Klein TE, et al. Standardizing CYP 2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and dutch pharmacogenetics working group. Clinical Translational Sci. 2020;13:116\u201324.","journal-title":"Clinical Translational Sci"},{"key":"428_CR41","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/cpt.2246","volume":"110","author":"MM Juki\u0107","year":"2021","unstructured":"Juki\u0107 MM, Smith RL, Molden E, Ingelman\u2010Sundberg M. Evaluation of the CYP2D6 haplotype activity scores based on metabolic ratios of 4700 patients treated with three different CYP2D6 substrates. Clin Pharma and Therapeutics. 2021;110:750\u20138.","journal-title":"Clin Pharma and Therapeutics"},{"key":"428_CR42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry. 1960;23:56\u201362.","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"428_CR43","volume-title":"ECDEU Assessment Manual for Psychopharmacology: Revised Edition","author":"W Guy","year":"1976","unstructured":"Guy W. ECDEU Assessment Manual for Psychopharmacology: Revised Edition. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976."},{"key":"428_CR44","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","volume":"67","author":"AT Beck","year":"1996","unstructured":"Beck AT, Steer RA, Ball R, Ranieri WF. Comparison of beck depression inventories-IA and-II in psychiatric outpatients. Journal of Personality Assessment. 1996;67:588\u201397.","journal-title":"Journal of Personality Assessment"},{"key":"428_CR45","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/070674370204700208","volume":"47","author":"J Vanderkooy","year":"2002","unstructured":"Vanderkooy J, Ken Nedy SNH, Bagby RMC. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry. 2002;47:174\u201380.","journal-title":"Can J Psychiatry"},{"key":"428_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/bmjebm-2020-111600","volume":"27","author":"MP Hengartner","year":"2022","unstructured":"Hengartner MP, Pl\u00f6derl M. Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression. BMJ EBM. 2022;27:69\u201373.","journal-title":"BMJ EBM"},{"key":"428_CR47","doi-asserted-by":"publisher","unstructured":"Pocock SJ Clinical trials: a practical approach. 1st edn Wiley, 2013 https:\/\/doi.org\/10.1002\/9781118793916.","DOI":"10.1002\/9781118793916"},{"key":"428_CR48","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1192\/bjp.174.4.297","volume":"174","author":"P Bollini","year":"1999","unstructured":"Bollini P, Pampaliona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants: Meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry. 1999;174:297\u2013303.","journal-title":"Br J Psychiatry"},{"key":"428_CR49","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/da.21918","volume":"29","author":"Carter","year":"2012","unstructured":"Carter, Cantrell GC, Victoria Zarotsky RA, Haynes VS, Phillips G, Alatorre CI, et al. Comprehensive review of factors implicated in the heterogeneity of response in depression: review: heterogeneity in depression. Depress Anxiety. 2012;29:340\u201354.","journal-title":"Depress Anxiety"},{"key":"428_CR50","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/cpt.2354","volume":"110","author":"EJ Cicali","year":"2021","unstructured":"Cicali EJ, Elchynski AL, Cook KJ, Houder JT, Thomas CD, Smith DM, et al. How to integrate CYP2D6 phenoconversion into clinical pharmacogenetics: a tutorial. Clin Pharmacol Ther. 2021;110:677\u201387.","journal-title":"Clin Pharmacol Ther"},{"key":"428_CR51","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E Von Elm","year":"2008","unstructured":"Von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Journal of Clinical Epidemiology. 2008;61:344\u20139.","journal-title":"Journal of Clinical Epidemiology"},{"key":"428_CR52","doi-asserted-by":"publisher","first-page":"13459","DOI":"10.3390\/ijms241713459","volume":"24","author":"J Maciaszek","year":"2023","unstructured":"Maciaszek J, Paw\u0142owski T, Hadry\u015b T, Machowska M, Wiela-Hoje\u0144ska A, Misiak B. The impact of the CYP2D6 and CYP1A2 gene polymorphisms on response to duloxetine in patients with major depression. IJMS. 2023;24:13459.","journal-title":"IJMS"},{"key":"428_CR53","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1001\/jamapsychiatry.2020.3643","volume":"78","author":"F Milosavljevic","year":"2021","unstructured":"Milosavljevic F, Bukvic N, Pavlovic Z, Miljevic C, Pe\u0161ic V, Molden E, et al. Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78:270.","journal-title":"JAMA Psychiatry"},{"key":"428_CR54","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2215-0366(19)30088-4","volume":"6","author":"MM Jukic","year":"2019","unstructured":"Jukic MM, Smith RL, Haslemo T, Molden E, Ingelman-Sundberg M. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. The Lancet Psychiatry. 2019;6:418\u201326.","journal-title":"The Lancet Psychiatry"},{"key":"428_CR55","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2217\/pgs-2017-0142","volume":"19","author":"LK Montan\u00e9 Jaime","year":"2018","unstructured":"Montan\u00e9 Jaime LK, Paul J, Lalla A, Legall G, Gaedigk A. Impact of CYP2D6 on venlafaxine metabolism in trinidadian patients with major depressive disorder. Pharmacogenomics. 2018;19:197\u2013212.","journal-title":"Pharmacogenomics"},{"key":"428_CR56","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/mp.2012.42","volume":"18","author":"JC Stingl","year":"2013","unstructured":"Stingl JC, Brockm\u00f6ller J, Viviani R. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry. 2013;18:273\u201387.","journal-title":"Mol Psychiatry"},{"key":"428_CR57","unstructured":"Kane M CYP2D6 overview: allele and phenotype frequencies. In: Medical Genetics Summaries. US; National Center for Biotechnology Information: 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK574601\/. Accessed 23 June2025."}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00428-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00428-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00428-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:02:47Z","timestamp":1793152967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00428-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["428"],"URL":"https:\/\/doi.org\/10.1038\/s41397-026-00428-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7234296\/v1","asserted-by":"object"}]},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MJ is a cofounder and executive director of TDM health. All other authors declare no competing interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"34"}}